



HAL
open science

Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond

Deepak Kumar, Sulgey Gauthami, Jagadeesh Bayry, Srinivas Kaveri,
Nagendra Hegde

► **To cite this version:**

Deepak Kumar, Sulgey Gauthami, Jagadeesh Bayry, Srinivas Kaveri, Nagendra Hegde. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*, 2021, 40 (2), pp.36-49. 10.1089/mab.2021.0004 . hal-03452618

HAL Id: hal-03452618

<https://hal.sorbonne-universite.fr/hal-03452618>

Submitted on 27 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Monoclonal Antibodies
in Immunodiagnosis
and Immunotherapy**

Hybridoma: <http://mc.manuscriptcentral.com/hybridoma>

Antibody therapy: from diphtheria to cancer, COVID-19 and beyond

Journal:	<i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i>
Manuscript ID	Draft
Manuscript Type:	Perspective
Date Submitted by the Author:	n/a
Complete List of Authors:	Kumar, Deepak; Ella Foundation Gauthami, Sulgey; National Institute of Animal Biotechnology Bayry, Jagadeesh; Indian Institute of Technology Palakkad Kaveri, Srin; INSERM U316 Hegde, Nagendra; National Institute of Animal Biotechnology,
Keyword:	Antibodies, Therapy, Immunoglobulin, Immunotherapy, Monoclonal Antibodies (MAb)
Manuscript Keywords (Search Terms):	Antibodies, Therapy, Cancer, Infectious Disease

SCHOLARONE™
Manuscripts

Antibody therapy: from diphtheria to cancer, COVID-19 and beyond

Deepak Kumar¹, Sulgey Gauthami², Jagadeesh Bayry^{3,4}, Srinivas V. Kaveri^{3,5} Nagendra R.

Hegde²

¹ Ella Foundation, Genome Valley, Turkapally, Shameerpet Mandal, Hyderabad – 500078, India

² National Institute of Animal Biotechnology, Opp. Journalist Colony, Extended Q City Road,
Near Gowlidoddi, Gachibowli, Hyderabad – 500032, India

³ Institut National de la Santé et de la Recherche Médicale (INSERM) Unite 1138, Sorbonne
Université, Centre de Recherche des Cordeliers, 15, Rue de l'Ecole de Médecine, 75006 Paris,
France

⁴ Indian Institute of Technology Palakkad, Palakkad, Kerala – 678557, India

⁵ Institut National de la Santé et de la Recherche Médicale (INSERM) Unite 872, Centre de
Recherche des Cordeliers, 15, Rue de l'Ecole de Médecine, 75006 Paris, France

⁵ Centre National de la Recherche Scientifique (CNRS) Bureau India, IFI, 2 Dr APJ Abdul
Kalam Road, New Delhi – 110001, India

Correspondance :

Nagendra R. Hegde (hegde@niab.org.in)

Srinivas Kaveri (srini.kaveri@cnrs.fr)

Abstract

The dawn of the 20th century saw the formative years of developments in immunology. In particular, immunochemistry, specifically pertaining to antibodies was extensively studied. These studies laid the foundations for employing antibodies in a variety of ways. Not surprisingly, antibodies have been used for applications ranging from biomedical research to disease diagnostics and therapeutics to evaluation of immune responses during natural infection and those elicited by vaccines. Despite recent advancements in cellular immunology and the excitement of T cell therapy, use of antibodies represents a large proportion of immunotherapeutic approaches as well as clinical interventions. Polyclonal antibodies in the form of plasma or sera continue to be used to treat a number of diseases including autoimmune disorders, cancers and infectious diseases. Historically, antisera to toxins have been the longest serving biotherapeutics. In addition, intravenous immunoglobulins (IVIg) have been extensively used to treat not only immunodeficiency conditions but also autoimmune disorders. Beyond the simplistic suppositions of their action, the IVIg have also unraveled the immune regulatory and homeostatic ramifications of their use. The advent of monoclonal antibodies (MAbs), on the other hand, have provided a clear pathway for their development of as drug molecules. MAbs have found a clear place in the treatment of cancers and extending lives and have been used in a variety of other conditions. In this review, we capture the important developments in the therapeutic applications of antibodies to alleviate disease, with a focus on some of the recent developments.

Introduction

Antibodies are indispensable components of the immune system. The tryst of antibodies with therapeutic applications began with Emil von Behring and Paul Ehrlich at the end of the 19th century into the 20th century. Combined with the seminal work of Karl Landsteiner and the exemplary contributions of a host of other scientists, the early part of the 20th century set the stage for the understanding of antibodies as biochemical molecules and their functional characteristics. Furthermore, hybridoma technology provided the much-needed impetus to take antibody to a whole new level of wide-ranging applications in medical interventions. Antibodies are now a versatile tool for diagnostics and therapy of various conditions in humans and animals.

Serum/plasma therapy

Serum or plasma therapy involves the passive transfer of pre-existing or pre-formed antibodies and serves as a ready-made armor against pathogens which have invaded the body. Plasma/serum therapy has been used against toxins, poisons & venoms, and infectious agents, including for the first time in any pandemic, the 1918 influenza pandemic, where serum from recovered patients was used to treat acutely ill patients [1]. By the early 20th century, plasma therapy was employed for the treatment of bacterial infections [2] and viral diseases such as measles [3] and polio[4]. The discovery of antibody purification through ethanol fractionation of plasma [5] was later adapted for many polyclonal antibody products.

The diphtheria antitoxin can neutralize the circulating toxin and has been used for clinical treatment since the late 1800s [6,7]. Similarly, the botulinum antitoxin effectively binds to the free toxin in the blood and prevents the progression of the symptoms, although it cannot reverse the paralysis that has already set in [8]. Antivenins were first successfully used in humans in

1
2
3 1896 [9]. The antivenins are typically produced against poisons of various animal species, most
4 commonly snakes, spiders and jellyfish, existing in the pertinent geographic regions, and are
5
6 either whole IgG molecules or the F(ab')₂ or Fab fragments.
7
8
9

10 Treatment with antibodies has also been employed against several viruses. The smallpox
11 vaccine was frequently associated with a number of serious adverse events (SAE), which had to
12 be managed by administering the vaccinia immune globulin (VIG). The VIG was also used to
13 prevent smallpox among close contacts of patients with the disease [10]. Post-exposure
14 prophylaxis of rabies involves a combination of active immunization and passive Ig therapy. The
15 anti-rabies Ig is typically derived from vaccinated equines or humans, but these are gradually
16 being replaced by monoclonal antibodies (MAbs) [11,12]. Hepatitis B immune globulin (HBIG)
17 is used to provide short-term protection against hepatitis B infection. A combination of hepatitis
18 B vaccine and one dose of HBIG produces immediate and sustained high levels of protective
19 antibody against hepatitis B [13]. The HBIG is also being explored in the treatment of chronic
20 hepatitis B [14]. Varicella zoster immunoglobulin (VZIG) is administered to reduce the severity
21 of the disease [15,16]. Virus neutralizing antibodies (NAb) targeting the epitopes on the
22 varicella-zoster virus (VZV) envelope fusion proteins gH or gH-gL complex, which mediate
23 virus entry, may replace the VZIG for antibody therapy [17,18]. In the case of human
24 cytomegalovirus (HCMV), identification of potent neutralizing antibodies against the HCMV
25 gH/gL/pUL128-131 complex [19,20] has led to the development of therapeutic antibodies to
26 improve transplantation outcomes [21]. For respiratory syncytial virus (RSV), various polyclonal
27 antibody and MAb formulations are being explored for their therapeutic potential [22,23].
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Specific plasma therapy received renewed attention in recent times for use against deadly
53 infectious diseases. One such disease is the Middle Eastern Respiratory Syndrome (MERS),
54
55
56
57

1
2
3 caused by MERS coronavirus (MERS-CoV), which has a case fatality rate of 35%. Owing to the
4
5 small number of donors and insufficient antibody titers in convalescent plasma, establishing
6
7 homo-specific plasma therapy for MERS has been difficult, and hence, equine and dromedary
8
9 camel antibodies have been explored as alternatives [24,25]. Serum from dromedary camels was
10
11 demonstrated to reduce the severity of the lung pathology and viral load in a mouse model [25].
12
13 Similarly, purified equine IgG and F(ab')₂ raised against MERS-CoV was demonstrated to
14
15 neutralize the virus *in vitro*, and reduced the virus load in a mouse model [24]. However, neither
16
17 have been used for treatment of humans suffering from MERS. During the Ebolavirus disease
18
19 (EVD) outbreak in 2013–2016, antibody-based treatments were evaluated for their preventive or
20
21 therapeutic potential. Plasma therapy for EVD was found to be safe, but no significant survival
22
23 benefit was recorded [26]. Polyclonal sera produced in cattle engineered to generate human
24
25 antibodies (transchromosomic cows) provided 90% protection in a mouse model of lethal EVD
26
27 [27], and protected all the treated non-human primates (NHPs) when administered on 1st or 3rd
28
29 day post-challenge [28]. In addition, anti-MERS-CoV antibodies produced in transchromosomic
30
31 cows were found to be safe in Phase I clinical trials [29].
32
33
34
35
36
37

38
39 A major application of plasma/serum therapy against infectious disease has been during
40
41 the currently on-going pandemic of coronavirus disease – 2019 (COVID-19), which is caused by
42
43 severe acute respiratory syndrome CoV-2 (SARS-CoV-2). In the initial phase of the pandemic,
44
45 this was the only option that was explored. This stemmed from the fact that infusion of
46
47 convalescent plasma was found to provide beneficial clinical outcome against SARS [30], which
48
49 is caused by the related virus, SARS-CoV-1. Several studies, including randomized controlled
50
51 trials (RCTs) as well as observational studies, showed favorable trends in terms of viral load,
52
53 oxygen demand, progression to intensive care, recovery time and/or death [31-33].
54
55
56
57

1
2
3 Mechanistically, besides the obvious effect of antibodies, the reversals in disease severity could
4 be attributed to transient reduction in detrimental cytokines and changes in lymphocyte
5 subpopulations [34]. However, plasma therapy could not attain the status of standard care owing
6 to its application based on clinician's judgment of risk versus benefit to individual patients, lack
7 of sufficient data from RCTs and uncertainties about its efficacy.
8
9

10
11 Polyclonal antibodies contained in the plasma/serum target multiple epitopes and are
12 likely to protect even against escape mutants of pathogens. However, the disadvantages of the
13 use of plasma/serum are batch-to-batch inconsistencies [35], low content of specific antibodies
14 [36,37], risks of adventitious agents [38], and development of allergic reactions [8]. In addition,
15 although robust neutralizing antibody (NAb) responses are produced against acute viral
16 infections in the majority of individuals, some viruses such as human immunodeficiency virus
17 (HIV) [39,40], influenza virus [41], Lassa virus [42,43], Ebola virus and SARS-CoV-2 [44] are
18 known to induce NAb responses at much lower levels, possibly making plasma therapy
19 ineffective for these viral infections. Variation in the structural proteins of viruses such as HIV
20 and influenza virus could also influence the success or failure of antibody therapy. Inconsistent
21 NAb titer in the convalescent plasma was a major drawback which limited its use against
22 COVID-19.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Intravenous immunoglobulin (IVIg) therapy**

45
46 Intravenous immunoglobulin (IVIg) is prepared from normal plasma obtained from
47 thousands of healthy donors. It consists of IgG, IgA, traces of other Ig's, cytokines, and soluble
48 receptors. The IVIg preparations are approved for use in immunotherapy of a variety of diseases.
49
50
51
52
53
54
55
56
57
58
59
60

(a) neutralization of activated complement components [45-47]; (b) inhibition of activation and

1
2
3 functions of innate immune cells such as dendritic cells [48,49], monocytes, macrophages [50-
4 53], neutrophils [54] and NK cells [55,56]; (c) modulation of B cell functions [57,58] and its
5 6 activation through toll-like receptors (TLR) [59,60], B-cell receptors [61] and IL-4 + CD40 [62];
7 8 (d) enhancing the differentiation of plasma cells [63]; and (e) reciprocal regulation of regulatory
9 10 T (Treg) cells [64] and effector T cells such as Th1 and Th17 subsets, and downregulation of the
11 12 production of inflammatory cytokines [65-68].
13 14
15

16
17
18 Apart from their use in immune disorders, IVIg have been used for various human
19 20 infectious diseases. The beneficial effects of IVIg have been demonstrated against various
21 22 bacterial infections such as severe invasive group A streptococcal disease, streptococcal toxic
23 24 shock syndrome, necrotizing *Staphylococcus aureus* sepsis, recurrent bacterial infections in
25 26 patients with hypogammaglobulinemia, polyneuropathy associated with *Campylobacter jejuni*,
27 28 recurrent *Clostridium difficile* colitis, *Chlamydia* pneumonia and *Salmonella typhimurium*
29 30 infections. The IVIg therapy has anti-inflammatory effects and can neutralize bacterial toxins
31 32 with varying efficacy [69]. Higher doses of IVIg are recommended as a last resort of treatment
33 34 for specific conditions like recurrent *Clostridium difficile* colitis and other bacterial diseases.
35 36
37 IVIg were also demonstrated to be beneficial against viral infections and diseases such as West
38 39 Nile, childhood HIV, parvovirus B19, HCMV-induced pneumonitis following transplantation,
40 41 genital herpes, enteroviruses and VZV. Further details about the applications of IVIg in
42 43 infectious diseases are reviewed elsewhere [70,71].
44 45
46

47 **Monoclonal antibodies as therapeutic agents**

48
49
50
51 Monoclonal antibody (MAb) therapy has gained a lot of traction in recent times. MABs
52 53 bind to specific epitopes in the target antigen. Initially, the application of MABs was restricted to
54 55 development of diagnostics; therapeutic application was constrained by the immunogenic
56 57

1
2
3 potential and poor efficacy due to the lack of effector function associated with murine antibodies.

4
5 The United States Food and Drugs Administration (US FDA) approved the first therapeutic MAb
6
7 (muromonab-CD3) of murine origin in 1986. Subsequently, modified antibodies consisting of
8
9 murine variable domain and human constant domain were developed and shown to have lower
10
11 side-effects without compromising the binding ability and led to the approval of the chimeric
12
13 MAbs for various indications *viz.*, cancer, infectious diseases, genetic diseases, allergic
14
15 conditions, etc. The MAbs were further humanized to contain only the complementary-
16
17 determining region (CDR) of murine origin in a human antibody backbone, by employing the
18
19 CDR grafting technique [72]. The next generation antibodies were fully human MAbs generated
20
21 through phage display [73,74], transgenics [75,76] and B cell cloning techniques. MAbs
22
23 produced through phage display have been used to target tumor necrosis factor α (TNF α) [77],
24
25 B-lymphocyte stimulator [78], vascular endothelial growth factor receptor-2 [79], epidermal
26
27 growth factor receptor [80], interleukin-23 [81], programmed cell death ligand 1 [82], plasma
28
29 kallikrein [83], interferon γ (IFN γ) [84], and CD22 conjugated with a toxic fragment of
30
31 *Pseudomonas* exotoxin A [85]. The pioneering work on B cell cloning and expansion from
32
33 human peripheral blood mononuclear cells (PBMC's), followed by immortalization with
34
35 Epstein-Barr virus [86,87] or isolation of human PBMC's or plasmablasts and cloning the
36
37 antibody heavy and light chain genes [88-90] has advanced human MAb field rapidly. Numerous
38
39 human anti-SARS-CoV-2 MAb candidates have been derived from PBMC's and are under
40
41 various stages of development. Antibodies are also being engineered to be bi-specific, where
42
43 each arm is specific to a different antigen. There are multiple therapeutic bi-specific antibody
44
45 candidates under development and these are reviewed elsewhere [91].
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Immunotherapy is an emerging arena for the treatment of cancer [92-94], and
4 encompassed vaccines, oncolytic viruses, immune checkpoint regulators and adoptive transfer of
5 ex-vivo activated T and NK cells. In this review, we focus on MAb therapy of cancers.
6
7

8
9
10 Antibodies can recognize specific targets on tumor cells *via* their Fab domain and engage
11 components of the immune system *via* the Fc region to destroy the tumor cells. The IgG subclass
12 is mostly used in these treatments due to its ability to interact with the Fcγ receptor (FcγR) on
13 macrophages and natural killer cells which are crucial for anti-cancer immune functions. The
14 effector mechanisms are due to receptor or ligand blocking, and antibody- or complement-
15 mediated cytotoxicity or phagocytosis. MAbs may either directly attack the tumor cells or in can
16 be conjugated to a toxin, drug or a radioisotope which have antitumor effects [95].
17
18
19
20
21
22
23
24
25
26

27 Another way to treat cancers is to target immune check point mediators, which modulate
28 immune homeostasis and hence are necessary for self-tolerance. Tumor cells manipulate the
29 checkpoint by binding to T-cell receptors thereby switching them “off”. The immune checkpoint
30 inhibitors (ICI) prevent inactivation of T-cells thereby allowing them to eliminate the mutant
31 cells [96]. The targets of ICIs include cytotoxic T-lymphocyte associated protein 4 (CTLA-4),
32 programmed death protein-1 (PD-1) and its ligand PDL-1 [97,98]. The inhibitory receptor
33 CTLA-4 prevents T-cell activation when bound to the B7 receptor on APCs [99]. Ipilimumab,
34 the MAb against CTLA-4 was the first ICI approved by the US FDA for the treatment of
35 melanoma. However, the use of these antibodies had resulted in immune-related adverse events
36 (irAE) in 10-30% of the patients [100]. In case of PD-1 receptor, its binding to PDL-1 on tumor
37 cell suppresses T-cell activation. The anti-PD-1 antibodies, Pembrolizumab and Nivolumab and
38 the anti-PDL-1 antibodies, Atezolizumab, Avelumab and Duvalumab effectively inhibit the PD-1
39 and PDL-1 interaction, resulting in activation of T-cells. In clinical trials, a combination to
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Ipilimumab and Nivolumab has shown good clinical outcome in patients with metastatic
4 melanoma [101,102]. A list of MAbs approved for clinical use are provided in Table 1.
5
6
7

8 Among the infectious agents, viruses are obligate intracellular pathogens and are not
9 inhibited by antibiotics. Several therapeutic interventions have been devised against viral
10 infections [103]. In the case of rabies virus, cocktails consisting of two MAbs have been
11 demonstrated to have broader virus neutralizing ability compared to formulations with only one
12 MAb [11]. With RSV, Palivizumab, which recognizes an epitope in the fusion protein [104,105],
13 was shown to reduce hospitalization by 55% in premature infants and in those with
14 bronchopulmonary dysplasia [106].
15
16
17
18
19
20
21
22
23
24

25 Three MAb therapies have been evaluated in clinical trials against EVD. A single MAb,
26 mAb114, which targets the receptor binding domain (RBD) of the Ebola virus glycoprotein
27 (GP), was found to be effective [107]. REGN-EB3, a combination of three MAbs produced in
28 humanized mice [108,109], binds to non-overlapping epitopes of GP, and neutralizes Ebola virus
29 and triggers FcγRIIIa. Both mAb114 [110] and REGN-EB3 [111] have been found to be safe,
30 and to significantly reduce the high fatality rate of EVD in humans [112]. ZMapp, another
31 combination of three chimeric MAbs produced in the plant *Nicotiana benthamiana*, was superior
32 by 91.2% when compared to the standard of care alone [113].
33
34
35
36
37
38
39
40
41
42
43

44 Various approaches were followed for the development of neutralizing MAbs against
45 MERS-CoV. These were primarily derived from infected patients [114-118], immunized mice
46 [119-122] or naïve human antibody libraries [123-125]. Most of these antibodies target the RBD
47 of the MERS-CoV Spike protein and interfere in the virus entry through human dipeptidyl
48 peptidase-4. In a marmoset model of MERS, the MAb combination of REGN3048 and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 REGN3051 proved efficacious in a prophylactic regimen [117] and the Phase I human clinical
4 trial results are not yet published [126].
5
6

7 8 ***MAbs for COVID-19 therapy*** 9

10 Owing to the close relatedness of SARS-CoV-2 to SARS-CoV-1, initial efforts of MAb
11 therapy against the former focused on repurposing anti-SARS-CoV-1 MAbs with cross-
12 neutralizing activity against SARS-CoV-2 [127,128]. Later, memory B cells specific to the RBD
13 of SARS-CoV-2 S protein were used to generate SARS-CoV-2-specific IgG1 MAbs [129].
14 These antibodies block the interaction between SARS-CoV-2 and its receptor, angiotensin
15 converting enzyme – 2 (ACE2). Since then, several MAbs have been used in therapeutic
16 intervention of COVID-19. Most of them target the RBD and interfere with the RBD-ACE2
17 interaction, preventing the entry of SARS-CoV-2 into cells [130-135]. The list of MAbs that are
18 currently in various phases of clinical trial is provided in Table 2. In addition, antibodies binding
19 to the N-terminal domain of S protein [136,137] or a distinct proteoglycan epitope [138] have
20 been demonstrated to neutralize SARS-CoV-2, and could be developed for therapeutic purposes.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Therapeutic antibody preparations for COVID-19 with single NAb could be ineffective
37 over time due to the emergence of escape mutants, as demonstrated for instance with hepatitis B
38 virus [139] or RSV [104], or it can have a broader neutralizing ability as shown with rabies virus
39 [11] or SARS-CoV-2 [138]. The emergence of SARS-CoV-2 variants such as the UK variant
40 (SARS-CoV-2 VOC 202012/01) and the South African variant (SARS-CoV-2 501Y.V2) with
41 the potential to escape single MAb therapy has led to the viewpoint that combinatorial MAb
42 therapy is better for effective treatment [140].
43
44
45
46
47
48
49
50
51

52 A cocktail of REGN10933 and REGN10987, which target non-overlapping epitopes on
53 the SARS-CoV-2 spike protein is in Phase 3 clinical trials. This combination has been shown to
54
55
56
57
58
59
60

1
2
3 markedly reduce respiratory viral load in a non-human primate model, even when the animals
4
5 were challenged with 10-fold higher virus load [141]. In Phase 1-3 clinical trial, where non-
6
7 hospitalized COVID-19 positive patients were enrolled, this cocktail was able to reduce the viral
8
9 load by two logs as compared to subjects who received the placebo [142].
10
11

12 Another example of a cocktail is AZD7442, a combination of AZD8895/Tixagevimab
13
14 and AZD1061/Cilgavimab, which recognize non-overlapping epitopes on the RBD and function
15
16 in synergy [143,144]. These antibodies are optimized with half-life extension and reduced Fc
17
18 receptor binding and hence called Long Acting AntiBodies (LAAB). Based on the earlier studies
19
20 [145-147], the half-life extension is expected to protect from COVID-19 for 6 to 12 months and
21
22 the modification in the Fc region reduces the risk of antibody dependent enhancement (ADE) of
23
24 the disease. This AZD7442 cocktail demonstrated prophylactic and therapeutic efficacy in mice
25
26 transiently expressing ACE2 as well as in immunocompetent mice. Sotrovimab (VIR-7831) is a
27
28 human MAb was isolated from SARS-CoV-1 convalescent memory B cells. It recognizes a
29
30 proteoglycan motif, and its neutralization effect is due to steric interference rather than
31
32 competing with receptor attachment [138]. It is currently being evaluated in Phase III clinical
33
34 trial (NCT04545060).
35
36
37
38
39

40 Regdanvimab (CT-P59) is a human MAb which potently neutralizes SARS-CoV-2
41
42 isolates including the D614G variant without the ADE effect. Structural studies show that
43
44 Regdanvimab binds to the receptor-binding motif within SARS-CoV-2 RBD. CT-P59 was
45
46 initially shown to be effective against SARS-CoV-2 in pre-clinical studies in ferrets, hamsters
47
48 and rhesus monkeys [148]. Preliminary efficacy data indicate that CT-P59 significantly reduces
49
50 by >50% the proportion of patients requiring hospitalization or oxygen therapy, as compared to
51
52 the placebo group [149].
53
54
55
56
57
58
59
60

Another potential therapeutic NAb candidate named LY-CoV555 (Bamlanivimab) is not modified in the Fc region. Non-human primate challenge studies indicated that LY-CoV555 was effective in reducing the virus replication in the upper and the lower respiratory tract [150]. In Phase II clinical trials, a majority of the subjects showed viral clearance by day 11 [151]. In a randomized Phase II/III trial, however, Bamlanivimab monotherapy failed to significantly reduce viral load, but the combination therapy of Bamlanivimab and Etesevimab significantly reduced SARS-CoV-2 viral load at day 11 [152]. The clinical trial outcomes of other neutralizing MAb are yet to be published.

Another area of immunotherapy for COVID-19 has been to dampen the hyper-immune response which appears to be directly correlated with the severity of disease. Increased concentrations of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), $\text{INF}\gamma$, interleukin (IL)-1 β , IL-2, IL-6, IL-7, IL-8, IL-9, IL-17, C-X-C motif chemokine 10 (CXCL10), chemokine ligand 2 (CCL2), CCL3 and CCL4 have been observed in severely affected patients. Therefore, several of these cytokines and chemokines have been targeted for mitigating the inflammatory response, and include IL-6 receptor (IL-6R), IL-6, GM-CSF and IL-1 β . Summary of the status of these therapeutics are provided in Table 3.

Perspective

Antibody therapy has become pivotal against cancers and emerging pathogens, especially those pathogens that cause acute hemorrhagic fever or hyper-inflammatory conditions such as a cytokine storm. Both polyclonal (plasma/serum) and monoclonal antibody therapy have distinct advantages and disadvantages. Plasma/serum is very likely to contain multi-specific antibodies that can function through binding more than one region in an antigen or more than one antigen on a pathogen. Any inter-host variation in antigenic determinants of the pathogen is likely to be

1
2
3 circumvented by polyclonal antibodies. However, standardization in terms of quantifiable levels,
4
5 affinity and avidity, potency (e.g., neutralization levels) as well as freedom from adventitious
6
7 agents are an issue with plasma/serum therapy, besides hypersensitivity reactions related to the
8
9 use of sera from heterologous species as well as transfusion-related histo-incompatibility
10
11 reactions related to heterologous individuals are a deterrent for the use of convalescent or
12
13 immune plasma/sera. Additional challenges include acquiring patients, adequate availability of
14
15 plasma and harvesting at an appropriate time. On the other hand, MAbs provide high specificity,
16
17 consistent affinity and avidity, and antigen specificity, besides being amenable to reliable quality
18
19 control during the production process. However, single MAb therapy could be ineffective in
20
21 cases where the pathogen frequently mutates, or could even drive the emergence of variant
22
23 strains. Hence, recent research has focused on deriving MAbs reactive to conserved epitopes or
24
25 to use a combination of two or more MAbs together. And yet, clinical use of MAb has been
26
27 skewed towards treating cancer or to treat inflammatory conditions, whereas only a handful of
28
29 products are licensed for use against infectious diseases. However, together with the adoption of
30
31 standardized procedures for the production of therapeutic antibodies, and the collaborative
32
33 efforts driven by the COVID-19 pandemic, MAb therapy is likely become a benchmark for any
34
35 future infectious disease outbreaks.
36
37
38
39
40
41
42
43

44 **Author Disclosure Statements**

45
46
47 JB and SVK acknowledge the support of CSL Behring, France. JB also acknowledges the
48
49 support of Agence Nationale de la Recherche, France under the call "Flash COVID-19" (ANR-
50
51 20-COVI-0093-COVIMUNE). The work was conceived and structured by SVK, NRH and JB.
52
53
54 Acquisition of the literature and the writing was done by DK, SG and NRH; NRH, JB and SVK.
55
56
57
58
59
60

critically reviewed and revised the manuscript. All the authors declare that there are no competing interests.

References

- 1 Luke TC, Kilbane EM, Jackson JL, Hoffman SL: Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med* 2006;145:599-609.
- 2 Casadevall A, Scharff MD: Serum therapy revisited: animal models of infection and development of passive antibody therapy. *Antimicrob Agents Chemother* 1994;38:1695-1702.
- 3 Janeway CA: Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles. *Bull N Y Acad Med* 1945;21:202-222.
- 4 Hammon WM, Coriell LL, Wehrle PF, Stokes J, Jr.: Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. *J Am Med Assoc* 1953;151:1272-1285.
- 5 Kendrick DB: Blood program in World War II, Washington, D.C. : Office of the Surgeon General, Dept. of the Army : For sale by the Supt. of Docs., U.S. G.P.O, 1964,
- 6 MacGregor RR: *Corynebacterium diphtheriae* (Diphtheria), ed 8. Elsevier, 2015.
- 7 Acosta PLM, Susan Hariri, and Tejpratap S.P. Tiwari: Diphtheria; in Jennifer Hamborsky AK, Charles (Skip) Wolfe (ed): *Epidemiology and Prevention of Vaccine-Preventable Diseases*, 2020, pp 107-118.
- 8 Schussler E, Sobel, J., Hsu, J., Yu, P., Meaney-Delman, D., Grammer 3rd, L.C., Nowak-Wegrzyn, A.: Workgroup Report by the Joint Task Force Involving American Academy of

- 1
2
3 Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and
4
5 Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions
6
7 to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and
8
9 Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to
10
11 Botulinum Antitoxin: A Systematic Review. *Clin Infect Dis* 2017;66:S65-S72.
12
13
14
15 9 Calmette A: Sur le venin des serpents et sur l'emploi du sérum antivenimeux dans la
16
17 thérapeutique des morsures venimeuses chez l'homme et chez les animaux. *Annales de*
18
19 *l'Institut Pasteur* 1897;XII:214–237.
20
21
22 10 Wittek R: Vaccinia immune globulin: current policies, preparedness, and product safety
23
24 and efficacy. *Int J Infect Dis* 2006;10:193-201.
25
26
27 11 Ding L, Wu, M., Zhang, H., Zhu, X., Hu Y., Li, X., Liu, J., Tsao, E., Liu, M., Li C.: Safety,
28
29 pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a
30
31 rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese
32
33 subjects. *Antiviral Res* 2020;184:104956.
34
35
36 12 WHO: Rabies monoclonal antibodies post exposure prophylaxis World Health
37
38 Organization, 2016,
39
40 13 Szmuness W, Stevens CE, Oleszko WR, Goodman A: Passive-active immunisation against
41
42 hepatitis B: immunogenicity studies in adult Americans. *Lancet* 1981;1:575-577.
43
44
45 14 NIH: Hepatitis B Immune Globulin (HBIG) to Restore Immune Control in People With
46
47 Chronic Hepatitis B, 2018,
48
49 15 CPS: Varicella zoster immune globulin use in neonates and infants. *Can J Infect Dis*
50
51 1996;7:17-18.
52
53
54
55
56
57
58
59
60

- 1
2
3 16 Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio
4
5 MA, LeGore J: Evaluation of varicella-zoster immune globulin: protection of
6
7 immunosuppressed children after household exposure to varicella. *J Infect Dis*
8
9 1983;147:737-743.
10
11
12 17 Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N, Seitz S, Azarkh Y,
13
14 Mahalingam R, Gilden D, Cohrs RJ: Human anti-varicella-zoster virus (VZV) recombinant
15
16 monoclonal antibody produced after Zostavax immunization recognizes the gH/gL
17
18 complex and neutralizes VZV infection. *J Virol* 2013;87:415-421.
19
20
21 18 Rodriguez JE, Moninger T, Grose C: Entry and egress of varicella virus blocked by same
22
23 anti-gH monoclonal antibody. *Virology* 1993;196:840-844.
24
25
26 19 Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G,
27
28 Sallusto F, Lanzavecchia A: Isolation of human monoclonal antibodies that potently
29
30 neutralize human cytomegalovirus infection by targeting different epitopes on the
31
32 gH/gL/UL128-131A complex. *J Virol* 2010;84:1005-1013.
33
34
35 20 Ha S, Li F, Troutman MC, Freed DC, Tang A, Loughney JW, Wang D, Wang IM, Vlasak
36
37 J, Nickle DC, Rustandi RR, Hamm M, DePhillips PA, Zhang N, McLellan JS, Zhu H,
38
39 Adler SP, McVoy MA, An Z, Fu TM: Neutralization of Diverse Human Cytomegalovirus
40
41 Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
42
43
44 *J Virol* 2017;91
45
46
47 21 Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R,
48
49 Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E,
50
51 Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, Segal F: Phase 2 Study of
52
53
54
55
56
57
58
59
60

- 1
2
3 Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic
4 Cell Transplantation. *Antimicrob Agents Chemother* 2020;64
5
6
7
8 22 Soto JA, Galvez NMS, Pacheco GA, Bueno SM, Kalergis AM: Antibody development for
9 preventing the human respiratory syncytial virus pathology. *Mol Med* 2020;26:35.
10
11
12 23 Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, Ramilo O:
13 Development and clinical applications of novel antibodies for prevention and treatment of
14 respiratory syncytial virus infection. *Vaccine* 2017;35:496-502.
15
16
17
18
19 24 Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F,
20 Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, Xia X: Passive
21 immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine
22 immunoglobulin or immunoglobulin fragments in a mouse model. *Antiviral Res*
23
24
25
26
27
28
29
30
31 25 Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M: Passive immunotherapy
32 with dromedary immune serum in an experimental animal model for Middle East
33 respiratory syndrome coronavirus infection. *J Virol* 2015;89:6117-6120.
34
35
36
37
38 26 van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby
39 PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze
40 J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou
41 A, De Weggheleire A, Haba N: Evaluation of Convalescent Plasma for Ebola Virus
42 Disease in Guinea. *N Engl J Med* 2016;374:33-42.
43
44
45
46
47
48
49 27 Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S,
50 Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC,
51 Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA: Production of
52
53
54
55
56
57
58
59
60

- 1
2
3 Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in
4
5 Transchromosomal Cattle. *Sci Rep* 2016;6:24897.
6
7
8 28 Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN,
9
10 Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper
11
12 J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao
13
14 JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, Jahrling PB: Fully
15
16 Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates
17
18 Infected With Ebola Virus Makona Isolate. *J Infect Dis* 2018;218:S636-S648.
19
20
21 29 Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey
22
23 RT, Jr.: Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus
24
25 antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind,
26
27 single-dose-escalation study. *Lancet Infect Dis* 2018;18:410-418.
28
29
30 30 Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB,
31
32 Cheng G: Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin*
33
34 *Microbiol Infect Dis* 2005;24:44-46.
35
36
37 31 Casadevall A, Grossman BJ, Henderson JP, Joyner MJ, Shoham S, Pirofski LA, Paneth N:
38
39 The Assessment of Convalescent Plasma Efficacy against COVID-19. *Med (N Y)*
40
41 2020;1:66-77.
42
43
44 32 Devarasetti PK, Rajasekhar L, Baisya R, Sreejitha KS, Vardhan YK: A review of COVID-
45
46 19 convalescent plasma use in COVID-19 with focus on proof of efficacy. *Immunol Res*
47
48 2021
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 33 Khadka S, Nisar S, Syed NI, Shrestha DB, Budhathoki P: Different aspects of convalescent
4 plasma therapy for COVID-19 treatment; a critical review. *Immunopharmacol*
5
6
7
8 *Immunotoxicol* 2021;43:30-36.
9
- 10 34 Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Gallo JE, Salazar-Uribe JC,
11 Santander MJ, Cala MP, Zapata W, Zapata MI, Manrique R, Pardo-Oviedo JM, Camacho
12 B, Ramirez-Santana C, Anaya JM, group C-C-: COVID-19 convalescent plasma
13 composition and immunological effects in severe patients. *J Autoimmun* 2021;118:102598.
14
15
16
17
18
- 19 35 Felton LD: The Units of Protective Antibody in Antipneumococcus Serum and Antibody
20 Solution. *The Journal of Infectious Diseases* 1928;43:531-542.
21
22
23
- 24 36 Weisman LE, Cruess DF, Fischer GW: Opsonic activity of commercially available
25 standard intravenous immunoglobulin preparations. *Pediatr Infect Dis J* 1994;13:1122-
26 1125.
27
28
29
- 30 37 Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-
31 Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-
32 Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M: Feasibility of Using Convalescent
33 Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. *Emerg Infect Dis*
34 2016;22:1554-1561.
35
36
37
38
39
- 40 38 Slade HB: Human Immunoglobulins for intravenous use and hepatitis C viral transmission.
41
42
43
44
45
46
- 47 39 Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B,
48 Self S, Kalams S, Stamatatos L: Factors associated with the development of cross-reactive
49 neutralizing antibodies during human immunodeficiency virus type 1 infection. *J Virol*
50 2009;83:757-769.
51
52
53
54
55
56
57

- 1
2
3 40 Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L,
4
5 Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L: The neutralization
6
7 breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T
8
9 cell decline and high viral load during acute infection. *J Virol* 2011;85:4828-4840.
10
11
12 41 Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, Henry Dunand CJ, Taylor
13
14 WM, Lim S, Huang M, Qu X, Lee JH, Salgado-Ferrer M, Krammer F, Palese P, Wrammert
15
16 J, Ahmed R, Wilson PC: Immune history profoundly affects broadly protective B cell
17
18 responses to influenza. *Sci Transl Med* 2015;7:316ra192.
19
20
21 42 Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M,
22
23 Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden TA,
24
25 Lambert PH, Siegrist CA, Pinschewer DD: Arenavirus Glycan Shield Promotes
26
27 Neutralizing Antibody Evasion and Protracted Infection. *PLoS Pathog* 2015;11:e1005276.
28
29
30 43 Jahrling PB, Frame JD, Rhoderick JB, Monson MH: Endemic Lassa fever in Liberia. IV.
31
32 Selection of optimally effective plasma for treatment by passive immunization. *Trans R*
33
34 *Soc Trop Med Hyg* 1985;79:380-384.
35
36
37 44 Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C,
38
39 Schultze-Florey CR, Godecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A,
40
41 Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pohlmann S, Blasczyk R, Schulz TF,
42
43 Forster R: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected
44
45 COVID-19 convalescent patients revealed by two different detection methods. *Cell Mol*
46
47 *Immunol* 2020
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 45 Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect
4
5 in patients with dermatomyositis by blocking endomysial deposition of activated
6
7 complement fragments. *J Clin Invest* 1994;94:1729-1735.
8
9
- 10 46 Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, Jelezarova E, Spath
11
12 PJ: Intravenously applied IgG stimulates complement attenuation in a complement-
13
14 dependent autoimmune disease at the amplifying C3 convertase level. *Blood*
15
16 2004;103:465-472.
17
18
- 19 47 Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundyil J, Gelderblom M, Cheng YL,
20
21 Pavlovski D, Tang SC, Jo DG, Magnus T, Chan SL, Sobey CG, Reutens D, Basta M,
22
23 Mattson MP, Arumugam TV: Intravenous immunoglobulin protects neurons against
24
25 amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death
26
27 pathways. *J Neurochem* 2012;122:321-332.
28
29
- 30 48 Bayry J, Bansal K, Kazatchkine MD, Kaveri SV: DC-SIGN and alpha2,6-sialylated IgG Fc
31
32 interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic
33
34 cells. *Proc Natl Acad Sci U S A* 2009;106:E24; author reply E25.
35
36
- 37 49 Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler
38
39 A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV: Inhibition of maturation
40
41 and function of dendritic cells by intravenous immunoglobulin. *Blood* 2003;101:758-765.
42
43
- 44 50 Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM,
45
46 Kazatchkine MD, Haeffner-Cavaillon N: Selective induction of interleukin-1 receptor
47
48 antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous
49
50 immunoglobulin). *Eur J Immunol* 1995;25:1267-1273.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 51 Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv
4
5 LB: Fcγ₃-dependent inhibition of interferon-γ responses mediates
6
7 suppressive effects of intravenous immune globulin. *Immunity* 2007;26:67-78.
8
9
10 52 Kozicky LK, Zhao ZY, Menzies SC, Fidanza M, Reid GS, Wilhelmsen K, Hellman J,
11
12 Hotte N, Madsen KL, Sly LM: Intravenous immunoglobulin skews macrophages to an
13
14 anti-inflammatory, IL-10-producing activation state. *J Leukoc Biol* 2015;98:983-994.
15
16
17 53 Galeotti C, Hegde P, Das M, Stephen-Victor E, Canale F, Munoz M, Sharma VK,
18
19 Dimitrov JD, Kaveri SV, Bayry J: Heme oxygenase-1 is dispensable for the anti-
20
21 inflammatory activity of intravenous immunoglobulin. *Sci Rep* 2016;6:19592.
22
23
24 54 Casulli S, Topcu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, Bayry J, Kaveri
25
26 SV, Elbim C: A differential concentration-dependent effect of IVIg on neutrophil
27
28 functions: relevance for anti-microbial and anti-inflammatory mechanisms. *PLoS One*
29
30 2011;6:e26469.
31
32
33 55 Ruiz JE, Kwak JY, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, Beer AE:
34
35 Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with
36
37 recurrent spontaneous abortion. *Am J Reprod Immunol* 1996;35:370-375.
38
39
40 56 Finberg RW, Newburger JW, Mikati MA, Heller AH, Burns JC: Effect of high doses of
41
42 intravenously administered immune globulin on natural killer cell activity in peripheral
43
44 blood. *J Pediatr* 1992;120:376-380.
45
46
47 57 Paquin Proulx D, Aubin E, Lemieux R, Bazin R: Inhibition of B cell-mediated antigen
48
49 presentation by intravenous immunoglobulins (IVIg). *Clin Immunol* 2010;135:422-429.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 58 Seite JF, Goutsmedt C, Youinou P, Pers JO, Hillion S: Intravenous immunoglobulin
4 induces a functional silencing program similar to anergy in human B cells. *J Allergy Clin*
5
6 *Immunol* 2014;133:181-188 e181-189.
7
8
9
10 59 Seite JF, Guerrier T, Cornec D, Jamin C, Youinou P, Hillion S: TLR9 responses of B cells
11 are repressed by intravenous immunoglobulin through the recruitment of phosphatase. *J*
12 *Autoimmun* 2011;37:190-197.
13
14
15
16
17 60 Kessel A, Peri R, Haj T, Snir A, Slobodin G, Sabo E, Rosner I, Shoenfeld Y, Toubi E:
18
19 IVIg attenuates TLR-9 activation in B cells from SLE patients. *J Clin Immunol*
20
21 2011;31:30-38.
22
23
24 61 Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S: IVIg modulates
25
26 BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes.
27
28 *Blood* 2010;116:1698-1704.
29
30
31 62 Zhuang Q, Bisotto S, Fixman ED, Mazer B: Suppression of IL-4- and CD40-induced B-
32
33 lymphocyte activation by intravenous immunoglobulin is not mediated through the
34
35 inhibitory IgG receptor FcγRIIb. *J Allergy Clin Immunol* 2002;110:480-483.
36
37
38 63 de Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S: Intravenous immunoglobulins
39
40 induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. *Blood*
41
42 2003;101:3065-3073.
43
44
45 64 Bayry J, Mouthon L, Kaveri SV: Intravenous immunoglobulin expands regulatory T cells
46
47 in autoimmune rheumatic disease. *J Rheumatol* 2012;39:450-451.
48
49
50 65 Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J: Inhibition of
51
52 differentiation, amplification, and function of human TH17 cells by intravenous
53
54 immunoglobulin. *J Allergy Clin Immunol* 2011;127:823-830 e821-827.
55
56
57
58
59
60

- 1
2
3 66 Maddur MS, Kaveri SV, Bayry J: Comparison of different IVIg preparations on IL-17
4 production by human Th17 cells. *Autoimmun Rev* 2011;10:809-810.
5
6
7
8 67 Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, Magy L, Bayry J, Kaveri
9 SV: Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and
10 regulatory T cells in Guillain-Barre syndrome patients. *Immunol Res* 2014;60:320-329.
11
12
13
14 68 Saha C, Das M, Patil V, Stephen-Victor E, Sharma M, Wymann S, Jordi M, Vonarburg C,
15 Kaveri SV, Bayry J: Monomeric Immunoglobulin A from Plasma Inhibits Human Th17
16 Responses In Vitro Independent of Fc α RI and DC-SIGN. *Front Immunol* 2017;8:275.
17
18
19
20
21 69 Schrage B, Duan G, Yang LP, Fraser JD, Proft T: Different preparations of intravenous
22 immunoglobulin vary in their efficacy to neutralize streptococcal superantigens:
23 implications for treatment of streptococcal toxic shock syndrome. *Clin Infect Dis*
24 2006;43:743-746.
25
26
27
28
29
30
31 70 Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Intravenous immunoglobulin
32 for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? *Trends*
33 *Pharmacol Sci* 2004;25:306-310.
34
35
36
37
38 71 Bulletin: I.V. immunoglobulin therapy for infectious diseases. *Drug Ther Bull* 2010;48:57-
39 60.
40
41
42
43 72 Jones PT, Dear PH, Foote J, Neuberger MS, Winter G: Replacing the complementarity-
44 determining regions in a human antibody with those from a mouse. *Nature* 1986;321:522-
45 525.
46
47
48
49 73 Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens
50 on the virion surface. *Science* 1985;228:1315-1317.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 74 McCafferty J, Griffiths AD, Winter G, Chiswell DJ: Phage antibodies: filamentous phage
4 displaying antibody variable domains. *Nature* 1990;348:552-554.
5
6
7
8 75 Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC,
9 Mashayekh R, Wymore K, McCabe JG, et al.: Antigen-specific human antibodies from
10 mice comprising four distinct genetic modifications. *Nature* 1994;368:856-859.
11
12
13
14 76 Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML,
15 Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F,
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 77 Kempeni J: Preliminary results of early clinical trials with the fully human anti-TNFalpha
monoclonal antibody D2E7. *Ann Rheum Dis* 1999;58 Suppl 1:I70-72.
- 78 Stohl W, Hilbert DM: The discovery and development of belimumab: the anti-BLyS-lupus
connection. *Nat Biotechnol* 2012;30:69-77.
- 79 Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C,
Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H,
Rowinsky EK, Eckhardt SG: Phase I pharmacologic and biologic study of ramucirumab
(IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the
vascular endothelial growth factor receptor-2. *J Clin Oncol* 2010;28:780-787.
- 80 Dienstmann R, Tabernero J: Necitumumab, a fully human IgG1 mAb directed against the
EGFR for the potential treatment of cancer. *Curr Opin Investig Drugs* 2010;11:1434-1441.
- 81 Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell
K, Marciniak SJ, Jr., Wasfi Y, Wang Y, Szapary P, Krueger JG: Guselkumab (an IL-23-

- specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. *J Allergy Clin Immunol* 2014;133:1032-1040.
- 82 Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016;17:1374-1385.
- 83 Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothhaft W, Maurer M: Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. *JAMA* 2018;320:2108-2121.
- 84 Cheloff AZ, Al-Samkari H: Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. *Drugs Today (Barc)* 2020;56:439-446.
- 85 Janus A, Robak T: Moxetumomab pasudotox for the treatment of hairy cell leukemia. *Expert Opin Biol Ther* 2019;19:501-508.
- 86 Aman P, Ehlin-Henriksson B, Klein G: Epstein-Barr virus susceptibility of normal human B lymphocyte populations. *J Exp Med* 1984;159:208-220.
- 87 Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A: An efficient method to make human monoclonal

- antibodies from memory B cells: potent neutralization of SARS coronavirus. *Nat Med* 2004;10:871-875.
- 88 Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat Protoc* 2009;4:372-384.
- 89 Obiakor H, Sehgal D, Dasso JF, Bonner RF, Malekafzali A, Mage RG: A comparison of hydraulic and laser capture microdissection methods for collection of single B cells, PCR, and sequencing of antibody VDJ. *Anal Biochem* 2002;306:55-62.
- 90 Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. *J Immunol Methods* 2008;329:112-124.
- 91 Labrijn AF, Janmaat ML, Reichert JM, Parren P: Bispecific antibodies: a mechanistic review of the pipeline. *Nat Rev Drug Discov* 2019;18:585-608.
- 92 Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH, Jr.: A review of cancer immunotherapy: from the past, to the present, to the future. *Curr Oncol* 2020;27:S87-S97.
- 93 Wahid B, Ali A, Rafique S, Waqar M, Wasim M, Wahid K, Idrees M: An overview of cancer immunotherapeutic strategies. *Immunotherapy* 2018;10:999-1010.
- 94 Waldman AD, Fritz JM, Lenardo MJ: A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* 2020;20:651-668.
- 95 Coulson A, Levy A, Gossell-Williams M: Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. *West Indian Med J* 2014;63:650-654.

- 1
2
3 96 Park R, Winnicki M, Liu E, Chu WM: Immune checkpoints and cancer in the
4 immunogenomics era. *Brief Funct Genomics* 2019;18:133-139.
5
6
7
8 97 Hargadon KM, Johnson CE, Williams CJ: Immune checkpoint blockade therapy for
9 cancer: An overview of FDA-approved immune checkpoint inhibitors. *Int*
10
11
12
13
14
15 98 He X, Xu C: Immune checkpoint signaling and cancer immunotherapy. *Cell Res*
16
17
18
19
20 99 Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4
21
22
23
24
25 100 Das S, Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune
26
27
28
29 101 Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD,
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 103 Hegde NR, Rao PP, Bayry J, Kaveri SV: Immunotherapy of viral infections.
46
47
48
49
50 104 Hashimoto K, Hosoya M: Neutralizing epitopes of RSV and palivizumab resistance in
51
52
53
54
55
56
57
58
59
60

- 1
2
3 105 Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL,
4
5
6
7
8
9
10
11 106 IMpact-RSV-Study-Group: Palivizumab, a humanized respiratory syncytial virus
12
13
14
15
16
17
18 107 Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose
19
20
21
22
23
24
25
26
27
28
29
30
31 108 Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL,
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- McCarthy MP, Van Nest G, Milich DR: Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. *J Clin Invest* 2015;125:1637-1647.
- Impact-RSV-Study-Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. *Pediatrics* 1998;102:531-537.
- Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. *Science* 2016;351:1339-1342.
- Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R, Jr., Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. *J Infect Dis* 2018;218:S612-S626.
- Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M: COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. *Antib Ther* 2020;3:205-212.

- 1
2
3 110 Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon
4
5 IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C,
6
7 Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT,
8
9 McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ,
10
11 Ledgerwood JE: Safety, tolerability, pharmacokinetics, and immunogenicity of the
12
13 therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608):
14
15 an open-label phase 1 study. *Lancet* 2019;393:889-898.
16
17
18
19 111 Sivapalasingam S, Kamal M, Slim R, Hosain R, Shao W, Stoltz R, Yen J, Pologe LG, Cao
20
21 Y, Partridge M, Sumner G, Lipsich L: Safety, pharmacokinetics, and immunogenicity of a
22
23 co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus
24
25 glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. *Lancet Infect*
26
27 *Dis* 2018;18:884-893.
28
29
30
31 112 Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M, Mukadi D,
32
33 Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S,
34
35 Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, Sivahera B, Camara M,
36
37 Kojan R, Walker R, Digheero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka
38
39 S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T,
40
41 Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E,
42
43 Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W,
44
45 Gettinger N, Vallee D, Nordwall J: A Randomized, Controlled Trial of Ebola Virus
46
47 Disease Therapeutics. *N Engl J Med* 2019;381:2293-2303.
48
49
50
51 113 Davey RT, Jr., Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS,
52
53 Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D: A
54
55
56
57
58
59
60

- 1
2
3 Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. *N Engl J Med*
4
5 2016;375:1448-1456.
6
7
8 114 Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, Yang JS, Kim JA, Yun MR,
9
10 Kim DW, Kim SS, Zhang Y, Shi W, Wang L, Graham BS, Mascola JR, Wang N,
11
12 McLellan JS, Lee JY, Lee H: Characterization of a human monoclonal antibody generated
13
14 from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory
15
16 syndrome coronavirus. *PLoS One* 2020;15:e0232757.
17
18
19 115 Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, Fernandez-Rodriguez B,
20
21 Foglierini M, Agatic G, Vanzetta F, Gopal R, Langrish CJ, Barrett NA, Sallusto F, Baric
22
23 RS, Varani L, Zambon M, Perlman S, Lanzavecchia A: Prophylactic and postexposure
24
25 efficacy of a potent human monoclonal antibody against MERS coronavirus. *Proc Natl*
26
27 *Acad Sci U S A* 2015;112:10473-10478.
28
29
30 116 de Wit E, Feldmann F, Horne E, Okumura A, Cameroni E, Haddock E, Saturday G, Scott
31
32 D, Gopal R, Zambon M, Corti D, Feldmann H: Prophylactic efficacy of a human
33
34 monoclonal antibody against MERS-CoV in the common marmoset. *Antiviral Res*
35
36 2019;163:70-74.
37
38
39 117 de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson
40
41 KJ, Stahl N, Lipsich L, Kyratsous CA, Feldmann H: Prophylactic and therapeutic efficacy
42
43 of mAb treatment against MERS-CoV in common marmosets. *Antiviral Res* 2018;156:64-
44
45 71.
46
47
48 118 Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ,
49
50 Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ,
51
52 Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR,
53
54
55
56
57
58
59
60

- 1
2
3 Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA: 3B11-N, a monoclonal
4 antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following
5 intratracheal inoculation of MERS-CoV Jordan-n3/2012. *Virology* 2016;490:49-58.
6
7
8
9
10 119 Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, Jiang S,
11 Li F, Zhou Y: A conformation-dependent neutralizing monoclonal antibody specifically
12 targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike
13 protein. *J Virol* 2014;88:7045-7053.
14
15
16
17
18
19 120 Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, Zhang B, Yuen
20 KY, Perlman S, Gao GF, Yan J: A humanized neutralizing antibody against MERS-CoV
21 targeting the receptor-binding domain of the spike protein. *Cell Res* 2015;25:1237-1249.
22
23
24
25
26 121 Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J,
27 Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W,
28 Yancopoulos GD, Stahl N, Frieman MB, Kyratsous CA: Pre- and postexposure efficacy of
29 fully human antibodies against Spike protein in a novel humanized mouse model of
30 MERS-CoV infection. *Proc Natl Acad Sci U S A* 2015;112:8738-8743.
31
32
33
34
35
36
37 122 Widjaja I, Wang C, van Haperen R, Gutierrez-Alvarez J, van Dieren B, Okba NMA, Raj
38 VS, Li W, Fernandez-Delgado R, Grosveld F, van Kuppeveld FJM, Haagmans BL,
39 Enjuanes L, Drabek D, Bosch BJ: Towards a solution to MERS: protective human
40 monoclonal antibodies targeting different domains and functions of the MERS-coronavirus
41 spike glycoprotein. *Emerg Microbes Infect* 2019;8:516-530.
42
43
44
45
46
47
48
49 123 Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L,
50 Yuen KY, Zheng BJ, Wang X, Zhang L: Potent neutralization of MERS-CoV by human
51
52
53
54
55
56
57
58
59
60

- neutralizing monoclonal antibodies to the viral spike glycoprotein. *Sci Transl Med* 2014;6:234ra259.
- 124 Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA: Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. *Proc Natl Acad Sci U S A* 2014;111:E2018-2026.
- 125 Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS: Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *J Virol* 2014;88:7796-7805.
- 126 NIH: A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051, 2017,
- 127 Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes Infect* 2020;9:382-385.
- 128 Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ: A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun* 2020;11:2251.
- 129 Chen X, Li R, Pan Z, Qian C, Yang Y, You R, Zhao J, Liu P, Gao L, Li Z, Huang Q, Xu L, Tang J, Tian Q, Yao W, Hu L, Yan X, Zhou X, Wu Y, Deng K, Zhang Z, Qian Z, Chen Y, Ye L: Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. *Cell Mol Immunol* 2020;17:647-649.

- 1
2
3 130 Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman
4
5 A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T,
6
7 Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O,
8
9 Rosenfeld R: A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at
10
11 multiple epitopes. *Nat Commun* 2020;11:4303.
12
13
14
15 131 Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, Wilson IA: A highly
16
17 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-
18
19 CoV. *Science* 2020;368:630-633.
20
21
22 132 Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X,
23
24 Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS,
25
26 Wang Q, Gao GF, Yuan Z, Yan J: A human neutralizing antibody targets the receptor-
27
28 binding site of SARS-CoV-2. *Nature* 2020;584:120-124.
29
30
31 133 Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J,
32
33 Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang
34
35 Z, Zhang L: Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
36
37 2020;584:115-119.
38
39
40 134 Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q,
41
42 Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF,
43
44 Wang X: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent
45
46 therapeutic antibody. *Science* 2020;369:1505-1509.
47
48
49 135 Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E,
50
51 Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E,
52
53 Fischinger S, Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J,
54
55
56
57
58
59
60

- 1
2
3 Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch
4
5 DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC: Persistence and
6
7 decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike
8
9 protein in COVID-19 patients. *Sci Immunol* 2020;5
10
11
12 136 Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y,
13
14 Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J,
15
16 Zhou Q, Chen W: A neutralizing human antibody binds to the N-terminal domain of the
17
18 Spike protein of SARS-CoV-2. *Science* 2020;369:650-655.
19
20
21 137 Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A,
22
23 Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski
24
25 JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD: Potent neutralizing antibodies against
26
27 multiple epitopes on SARS-CoV-2 spike. *Nature* 2020;584:450-456.
28
29
30 138 Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K,
31
32 Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE,
33
34 Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS,
35
36 Fink K, Veessler D, Corti D: Cross-neutralization of SARS-CoV-2 by a human monoclonal
37
38 SARS-CoV antibody. *Nature* 2020;583:290-295.
39
40
41 139 Golsaz Shirazi F, Mohammadi H, Amiri MM, Singethan K, Xia Y, Bayat AA, Bahadori M,
42
43 Rabbani H, Jeddi-Tehrani M, Protzer U, Shokri F: Monoclonal antibodies to various
44
45 epitopes of hepatitis B surface antigen inhibit hepatitis B virus infection. *J Gastroenterol*
46
47 *Hepatol* 2014;29:1083-1091.
48
49
50 140 Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon
51
52
53 K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J,
54
55
56
57
58
59
60

- 1
2
3 Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J,
4
5 Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A,
6
7 Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R,
8
9 Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA:
10 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody
11 cocktail. *Science* 2020;369:1010-1014.
12
13
14
15
16
17 141 Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K,
18
19 Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous
20 CA: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape
21 seen with individual antibodies. *Science* 2020;369:1014-1018.
22
23
24
25
26
27 142 Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y,
28 Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT,
29 Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva
30 Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G,
31 Yancopoulos GD, Trial I: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients
32 with Covid-19. *N Engl J Med* 2020
33
34
35
36
37
38
39
40 143 Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schafer A, Reidy JX,
41 Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC,
42 Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller
43 BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard
44 NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS,
45 Thackray LB, Diamond MS, Carnahan RH, Crowe JE, Jr.: Potently neutralizing and
46 protective human antibodies against SARS-CoV-2. *Nature* 2020;584:443-449.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 144 Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE,
4
5 Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE,
6
7 MacRenaris KW, Jones T, Day S, Myers L, Eun-Hyung Lee F, Nguyen DC, Sanz I,
8
9 Martinez DR, Rothlauf PW, Bloyet LM, Whelan SPJ, Baric RS, Thackray LB, Diamond
10
11 MS, Carnahan RH, Crowe JE, Jr.: Rapid isolation and profiling of a diverse panel of
12
13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nat Med*
14
15 2020;26:1422-1427.
16
17
18
19 145 Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP: A
20
21 novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE,
22
23 has an extended half-life in healthy adults. *Antimicrob Agents Chemother* 2013;57:6147-
24
25 6153.
26
27
28 146 Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky
29
30 F: Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial
31
32 Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy
33
34 Adults. *Antimicrob Agents Chemother* 2017;61
35
36
37 147 Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, Bellamy T, Hernandez-Illas
38
39 M, Jafri HS: Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational,
40
41 Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal
42
43 Antibody, in Healthy Adults. *Antimicrob Agents Chemother* 2017;61
44
45
46 148 Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae
47
48 JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon
49
50 KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM,
51
52 Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ,
53
54
55
56
57
58
59
60

- 1
2
3 Ryu CM, Park WB, Oh MD, Choi YK, Lee SY: A therapeutic neutralizing antibody
4 targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun
5
6 2021;12:288.
7
8
9
10 149 Ison MG: Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate
11 Symptoms of SARS CoV 2 Infection: eSymposia, Antibodies and Vaccines as Drugs for
12 COVID-19, Virtual Key Stone Symposia, 2021,
13
14
15 150 Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP,
16
17 Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D,
18
19 Wang L, Bidshahri R, Kraft L, Hwang Y, Zentelis S, Jepson KR, Goya R, Smith MA,
20
21 Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S,
22
23 Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez
24
25 DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed
26
27 A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV,
28
29 Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E:
30
31 LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-
32
33 human primate model of SARS-CoV-2 infection. bioRxiv 2020
34
35
36 151 Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla
37
38 B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley
39
40 G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM, Investigators B-: SARS-
41
42 CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med
43
44 2020
45
46
47 152 Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla
48
49 B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M,
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR,
4 Klekotka P, Shen L, Skovronsky DM: Effect of Bamlanivimab as Monotherapy or in
5
6 Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-
7
8
9
10
11
12
13 153 Fala L: Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for
14
15 Advanced Squamous Non-Small-Cell Lung Cancer. *Am Health Drug Benefits* 2016;9:119-
16
17 122.
18
19
20 154 Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S:
21
22 Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other
23
24 Solid Tumors. *Front Oncol* 2019;9:849.
25
26
27 155 Dubois EA, Cohen AF: Panitumumab. *Br J Clin Pharmacol* 2009;68:482-483.
28
29
30 156 Crombet Ramos T, Mestre Fernandez B, Mazorra Herrera Z, Iznaga Escobar NE:
31
32 Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. *Front Oncol*
33
34 2020;10:817.
35
36
37 157 Kazazi-Hyseni F, Beijnen JH, Schellens JH: Bevacizumab. *Oncologist* 2010;15:819-825.
38
39
40 158 Wu J, Fu J, Zhang M, Liu D: Blinatumomab: a bispecific T cell engager (BiTE) antibody
41
42 against CD19/CD3 for refractory acute lymphoid leukemia. *J Hematol Oncol* 2015;8:104.
43
44
45 159 Rizzieri D: Zevalin((R)) (ibritumomab tiuxetan): After more than a decade of treatment
46
47 experience, what have we learned? *Crit Rev Oncol Hematol* 2016;105:5-17.
48
49
50 160 Weiner GJ: Rituximab: mechanism of action. *Semin Hematol* 2010;47:115-123.
51
52
53 161 Biodrugs: Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-
54
55 CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-
56
57 131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. *BioDrugs* 2003;17:290-295.
58
59
60

- 1
2
3 162 Zhang B: Ofatumumab. *MAbs* 2009;1:326-331.
4
5
6 163 Tobinai K, Klein C, Oya N, Fingerle-Rowson G: A Review of Obinutuzumab (GA101), a
7
8 Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell
9
10 Malignancies. *Adv Ther* 2017;34:324-356.
11
12 164 Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X,
13
14 Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret
15
16 S, Dombret H, Castaigne S: Gemtuzumab ozogamicin for de novo acute myeloid leukemia:
17
18 final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
19
20 *Haematologica* 2019;104:113-119.
21
22 165 Sanchez L, Wang Y, Siegel DS, Wang ML: Daratumumab: a first-in-class CD38
23
24 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol* 2016;9:51.
25
26 166 Havrdova E, Horakova D, Kovarova I: Alemtuzumab in the treatment of multiple sclerosis:
27
28 key clinical trial results and considerations for use. *Ther Adv Neurol Disord* 2015;8:31-45.
29
30 167 Gemmete JJ, Mukherji SK: Trastuzumab (herceptin). *AJNR Am J Neuroradiol*
31
32 2011;32:1373-1374.
33
34 168 McDermott J, Jimeno A: Pembrolizumab: PD-1 inhibition as a therapeutic strategy in
35
36 cancer. *Drugs Today (Barc)* 2015;51:7-20.
37
38 169 Guo L, Zhang H, Chen B: Nivolumab as Programmed Death-1 (PD-1) Inhibitor for
39
40 Targeted Immunotherapy in Tumor. *J Cancer* 2017;8:410-416.
41
42 170 Gil-Bazo I: Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-
43
44 small cell lung cancer. *Transl Lung Cancer Res* 2017;6:S35-S38.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 171 Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A: Durvalumab: an
4
5 investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
6
7 Drug Des Devel Ther 2018;12:209-215.
8
9
10 172 Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS: Molecular
11
12 mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and
13
14 durvalumab. Sci Rep 2017;7:5532.
15
16
17 173 Magen H, Mughtar E: Elotuzumab: the first approved monoclonal antibody for multiple
18
19 myeloma treatment. Ther Adv Hematol 2016;7:187-195.
20
21
22 174 Dhillon S: Dinutuximab: first global approval. Drugs 2015;75:923-927.
23
24
25 175 Tarhini A, Lo E, Minor DR: Releasing the brake on the immune system: ipilimumab in
26
27 melanoma and other tumors. Cancer Biother Radiopharm 2010;25:601-613.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: List of US FDA approved MAbs for immunotherapy of cancer

Target	Drug	Clinical use	Ref
Epidermal growth factor receptor (EGFR)	Necitumumab	Squamous non–small-cell lung cancer	[153]
	Cetuximab	Colorectal, head and neck cancer	[154]
	Panitumumab	Colorectal cancer	[155]
	Nimotuzumab	Squamous cell carcinoma, glioma	[156]
Vascular endothelial growth factor (VEGF)	Bevacizumab	Anti-angiogenic therapy	[157]
CD19-directed CD3 T-cell engager	Blinatumomab	Acute lymphoblastic leukemia (ALL) Diffuse Large B-cell Lymphoma	[158]
CD20	Ibritumomab	Non-Hodgkin's lymphoma	[159]
	Rituximab	Non-Hodgkin's lymphoma	[160]
	Tositumomab	Non-Hodgkin's lymphoma	[161]
	Ofatumumab	Chronic lymphocyte leukemia and multiple sclerosis	[162]
	Obinutuzumab	chronic lymphocytic leukemia (in combination with chlorambucil)	[163]
CD33 (myeloid cell surface antigen on	Gemtuzumab	Acute myeloid leukaemia	[164]

leukemia cells)			
CD38	Daratumumab	Multiple myeloma.	[165]
CD52	Alemtuzumab	Chronic lymphocytic leukemia	[166]
Her2/neu receptor	Trastuzumab	Breast cancer	[167]
PD-1	Pembrolizumab	cervical cancer head and neck squamous cell carcinoma	[168]
	Nivolumab	Renal cell cancer Hodgkins lymphoma squamous cell carcinoma of the head and neck	[169]
PD-L1	Avelumab	Merkel cell carcinoma Non-small cell lung cancer	[170]
	Durvalumab	urothelial cancers Unresectable stage III non-small cell lung cancer	[171]
	Atezolizumab	In combination with carboplatin and etoposide for treatment of small cell lung cancer, In combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive	[172]

		unresectable or metastatic melanoma.	
SLAM F7	Elotuzumab	Multiple myeloma (used in combination with lenalidomide and dexamethasone)	[173]
Disialoganglioside (GD2)	Dinutuximab	Neuroblastoma in pediatric patients	[174]
CTLA-4	Ipilimumab	Melanoma	[175]

Table 2: MABs against SARS-CoV-2 S protein that are in clinical trials*

Product Name	Status	Developer
REGN-COV2 (REGN10933/Casirivimab + REGN10987/Imdevimab)	Phase 3	Regeneron/NIAID
Bamlanivimab (LY3819253, LY-CoV555)	Phase 3	AbCellera/Eli Lilly/NIH
Sotrovimab (VIR- 7831/GSK4182136)	Phase 3	Vir biotechnology/GSK
AZD7442 (AZD8895/Tixagevimab + AZD1061/Cilgavimab)	Phase 3	AstraZeneca/Vanderbilt University Medical Center/DARPA/BARDA
Regdanvimab (CT-P59)	Phase 3	Celltrion
DXP-593	Phase 2	Beigene/Singlomics Biopharmaceuticals/Peking University
Etesevimab (JS016, LY- CoV016, LY3832479)	Phase 2	Junshi Biosciences/Institute of Microbiology, Chinese Academy of Sciences/Eli Lilly
DZIF-10c	Phase 2	University of Cologne/The German Center for Infection Research/ BoehringerIngelheim
COVI-AMG (STI-2020)	Phase 2	Sorrento Therapeutics
STI-1499/COVI-SHIELD	Phase 1	Sorrento/Mount Sinai Health System
TY027	Phase 1	Tychan

BRII-196	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University
BRII-198	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University
SCTA01	Phase 1	Sinocelltech Ltd/Chinese Academy of Sciences
MW33	Phase 1	Mabwell (Shanghai) Bioscience Co., Ltd.
HFB30132A	Phase 1	HiFiBiO Therapeutics
HLX70	Phase 1	Hengenix Biotech Inc
ADM03820	Phase 1	Ology Bioservices

*Table modified from COVID-19 Therapeutic Antibody Tracker to include the products which are in clinical trial

(<https://chineseantibody.org/covid-19-track>) [109]

Table 3: MAbs targeting the host proteins to treat COVID-19#

Product Name	Target	Status	Developer
Itolizumab (EQ001, H-T1, T1-h)	CD6	Approved	Biocon
Levilimab (BCD-089)	IL-6R	Approved	BIOCAD
Tocilizumab	IL-6R	Phase 4	Hoffmann-La Roche/multiple sponsors
Ravulizumab-cwvz	C5	Phase 4	Alexion Pharmaceuticals/Cambridge University Hospitals NHS Foundation Trust
Sarilumab (SAR153191, Kevzara)	IL-6R	Phase 4	Regeneron/Sanofi/multiple sponsors
Siltuximab	IL-6	Phase 3	University Hospital, Ghent/A.O. Ospedale Papa Giovanni XXIII
Lenzilumab	GM-CSF	Phase 3	Humanigen
Canakinumab	IL-1 β	Phase 3	Novartis
CD24Fc (SACCOVID)	DAMPs, Siglec G/10	Phase 3	OncoImmune
Olokizumab	IL-6	Phase 3	R-Pharm JSC/Cromos Pharma
Leronlimab (PRO-140)	CCR5	Phase 3	CytoDyn

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
Emapalumab (Gamifant)	IFN gamma	Phase 3	Swedish Orphan Biovitrum																																																								
Bevacizumab	VEGF	Phase 3	Qilu Hospital of Shandong University/Renmin Hospital of Wuhan University/IalyMoriggiaPelasi ciniGravedona Hospital S.p.A/Wuhan University/Jiangbei Union Hospital of Huazhong University of science and technology/Shandong Provincial Chest Hospital																																																								
IFX-1 (BDB-001)	C5a	Phase 3	Staidson/InflaRx/Beijing Defengrei Biotechnology																																																								
Clazakizumab	IL-6	Phase 3	Medical University of Vienna/NYU Langone Health																																																								
RPH-104	IL-1	Phase 3	R-Pharm JSC, Cromos Pharma																																																								
Pamrevlumab(FG-3019)	Connective tissue growth factor (CCN2)	Phase 3	FibroGen, Inc.																																																								

Mavrilimumab	GM-CSF receptor	Phase 3	Kiniksa Pharmaceuticals/multiple sponsors
UTTR1147A	IL-22R	Phase 2	Genentech
F-652	IL-22R	Phase 2	Generon(Shanghai) Corporation Ltd.
APG101	CD95 ligand	Phase 2	Apogenix GmbH
Crizanlizumab	P-selectin	Phase 2	Johns Hopkins University/Novartis/Socar Research SA/Brigham and Women's Hospital
Garadacimab (CSL312)	Factor XIIa	Phase 2	CSL Behring
Infliximab	TNF	Phase 2	Tufts Medical Center/NIH
APN01	SARS-CoV-2 S protein	Phase 2	APEIRON Biologics
Otilimab	GM-CSF	Phase 2	GSK
Avdoralimab	C5aR	Phase 2	Innate Pharma SA
Zansecimab (LY3127804)	Ang-2	Phase 2	Eli Lilly
Eculizumab	C5	Phase 2	Alexion Pharmaceuticals/Hudson Medical
Camrelizumab	PD-1	Phase 2	Jiangsu HengRuiMedicine/Southeast

			University/Wuhan Jinyintan Hospital
Pembrolizumab	PD-1	Phase 2	Medica Scientia Innovation Research (MEDSIR)
Gimsilumab	GM-CSF	Phase 2	Roivant Sciences
Ixekizumab	IL-17A	Phase 2	Xiangya Hospital of Central South University
BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018	IL-8	Phase 2	Bristol-Myers Squibb
Astegolimab	IL-33R	Phase 2	Genentech
Secukinumab (AIN457)	IL-17A	Phase 2	Lomonosov Moscow State University Medical Research and Educational Center
ATYR1923	Neuropilin-2	Phase 2	aTyr Pharma, Inc.
Axatilimab (SNDX-6352)	CSF-1R	Phase 2	Syndax Pharmaceuticals, Inc
NN8765, IPH-2201, NNC141-0100	NKG2A (CD159a)	Phase 2	Innate Pharma SA
CNTO 136	IL-6	Phase 2	Janssen
CERC-002	LIGHT	Phase 2	Cerecor
TJM2 (TJ003234)	GM-CSF	Phase 2	I-MAB
IC14	CD14	Phase 2	Implicit Bioscience
Meplazumab	CD147	Phase 2	Tang-Du Hospital
Adrecizumab(HAM8101)	Adrenomedulin	Phase 1	Adrenomed AG

CPI-006	CD73	Phase 1	Corvus Pharmaceuticals
hzVSFv13	Vimentin	Phase 1	ImmuneMed
Lanadelumab	kallikrein	Phase 1	Radboud University/Takeda
AK119	CD73	Phase 1	Akesobio
Daxdilimab (VBI7734)	ILT7	Phase 1	Viela Bio
Efineptakinalfa(GX-17)	IL-7R	Phase 1	NeoImmuneTech

Table modified from COVID-19 Therapeutic Antibody Tracker to include the products which are in clinical trial

(<https://chineseantibody.org/covid-19-track>) [109].